Medical Condition News

RSS

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Trial shows antiplatelet therapy needs personalization after stent implantation

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.

29 Aug 2026

Milvexian fails to reduce cardiovascular events after acute coronary syndrome

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.

29 Aug 2026

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

29 Aug 2026

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.

29 Aug 2026

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

REACT study maps widespread silent atherosclerosis across adult lifespan

Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to results from the REACT study presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Immediate evolocumab use after heart attack improves cholesterol goals but not survival

Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not observed compared with standard care.

29 Aug 2026

Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions

The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease.

29 Aug 2026

New study detects silent atherosclerosis in healthy young adults

Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.

29 Aug 2026

New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage

Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had had an intracranial hemorrhage, according to results presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase II TRANQUILITY trial presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Researchers identify early molecular warning signs of inflammatory bowel disease

Researchers have uncovered early molecular warning signs of inflammatory bowel disease, revealing the condition can begin before symptoms appear and continue silently even when patients appear well.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 29 Aug 2026

FAU researchers develop quantum machine learning framework for heart disease prediction

Cardiovascular disease remains a major global health challenge, causing millions of deaths each year and imposing substantial healthcare costs. Early, accurate diagnosis is critical for improving outcomes and enabling timely intervention.

29 Aug 2026

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

From Dana-Farber Cancer Institute, Inc. 29 Aug 2026

New research could improve how brain cancer and tumors are treated

Australian researchers are challenging decades-old assumptions about brain cancer treatment in a bid to make radiation therapy more effective against tumors, while reducing damage to healthy tissue.

29 Aug 2026

Primate-specific DNA change reveals a new link to dementia-related neurodegeneration

Brain diseases, including dementia, have long been studied using experimental animals such as mice. However, differences between the human and animal genomes have raised concerns that some disease mechanisms may not be fully explained by conventional animal models.

29 Aug 2026

Study identifies KRAS G12C as a precision-medicine target in genitourinary cancers

A new research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled "Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine."

28 Aug 2026

New stroke guidelines could help pave the way for precision rehabilitation

A University of Maryland School of Medicine (UMSOM) stroke rehabilitation specialist helped develop new recommendations for studying molecular biomarkers associated with recovery from stroke.

28 Aug 2026

Type 1 diabetes cases projected to increase worldwide by 2049

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049.

28 Aug 2026

Medical Condition News

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Trial shows antiplatelet therapy needs personalization after stent implantation

Milvexian fails to reduce cardiovascular events after acute coronary syndrome

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

REACT study maps widespread silent atherosclerosis across adult lifespan

Immediate evolocumab use after heart attack improves cholesterol goals but not survival

Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions

New study detects silent atherosclerosis in healthy young adults

New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage

Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

Researchers identify early molecular warning signs of inflammatory bowel disease

FAU researchers develop quantum machine learning framework for heart disease prediction

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

New research could improve how brain cancer and tumors are treated

Primate-specific DNA change reveals a new link to dementia-related neurodegeneration

Study identifies KRAS G12C as a precision-medicine target in genitourinary cancers

New stroke guidelines could help pave the way for precision rehabilitation

Type 1 diabetes cases projected to increase worldwide by 2049

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News